Therapeutic innovations in the management of juvenile arthritis

Abstract

Much remains to be learned about the optimal therapy for patients with juvenile arthritis. Better classification criteria, advances in knowledge of etiopathogenesis, and definition of uniform response criteria are all required. At the present time methotrexate is the only drug that has been shown to be superior to placebo in the treatment of juvenile arthritis. A review of current accepted management strategies is presented